Sid E O'Bryant1, Fan Zhang1,2, Melissa Petersen1,2, James R Hall1,3, Leigh A Johnson1,3, Kristine Yaffe4,5, Meredith Braskie6, Rocky Vig7, Arthur W Toga8, Robert A Rissman9,10. 1. Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA. 2. Department of Family Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA. 3. Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA. 4. Department of Psychiatry, Neurology, and Epidemiology and Biostatistics, University of California, San Francisco, CA, USA. 5. San Francisco VA Medical Center, San Francisco, CA, USA. 6. Imaging Genetics Center, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA. 7. Imaging, Midtown Medical Imaging, Fort Worth, TX, USA. 8. Laboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA. 9. Department of Neurosciences, University of California, San Diego, La Jolla, CA and Veterans Affairs San Diego Healthcare System, San Diego, CA, USA. 10. Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.
Abstract
BACKGROUND: Hispanics are expected to experience the largest increase in Alzheimer's disease (AD) and AD related dementias over the next several decades. However, few studies have examined biomarkers of AD among Mexican Americans, the largest segment of the U.S. Hispanic population. OBJECTIVE: We sought to examine proteomic profiles of an MRI-based marker of neurodegeneration from the AT(N) framework among a multi-ethnic, community-dwelling cohort. METHODS: Community-dwelling Mexican Americans and non-Hispanic white adults and elders were recruited. All participants underwent comprehensive assessments including an interview, functional exam, clinical labs, informant interview, neuropsychological testing, and 3T MRI of the brain. A neurodegeneration MRI meta-ROI biomarker for the AT(N) framework was calculated. RESULTS: Data was examined from n = 1,291 participants. Proteomic profiles were highly accurate for detecting neurodegeneration (i.e., N+) among both Mexican Americans (AUC = 1.0) and non-Hispanic whites (AUC = 0.98). The proteomic profile of N + was different between ethnic groups. Further analyses revealed that the proteomic profiles of N + varied by diagnostic status (control, MCI, dementia) and ethnicity (Mexican American versus non-Hispanic whites) though diagnostic accuracy was high for all classifications. CONCLUSION: A proteomic profile of neurodegeneration has tremendous value and point towards novel diagnostic and intervention opportunities. The current findings demonstrate that the underlying biological factors associated with neurodegeneration are different between Mexican Americans versus non-Hispanic whites as well as at different levels of disease progression.
BACKGROUND: Hispanics are expected to experience the largest increase in Alzheimer's disease (AD) and AD related dementias over the next several decades. However, few studies have examined biomarkers of AD among Mexican Americans, the largest segment of the U.S. Hispanic population. OBJECTIVE: We sought to examine proteomic profiles of an MRI-based marker of neurodegeneration from the AT(N) framework among a multi-ethnic, community-dwelling cohort. METHODS: Community-dwelling Mexican Americans and non-Hispanic white adults and elders were recruited. All participants underwent comprehensive assessments including an interview, functional exam, clinical labs, informant interview, neuropsychological testing, and 3T MRI of the brain. A neurodegeneration MRI meta-ROI biomarker for the AT(N) framework was calculated. RESULTS: Data was examined from n = 1,291 participants. Proteomic profiles were highly accurate for detecting neurodegeneration (i.e., N+) among both Mexican Americans (AUC = 1.0) and non-Hispanic whites (AUC = 0.98). The proteomic profile of N + was different between ethnic groups. Further analyses revealed that the proteomic profiles of N + varied by diagnostic status (control, MCI, dementia) and ethnicity (Mexican American versus non-Hispanic whites) though diagnostic accuracy was high for all classifications. CONCLUSION: A proteomic profile of neurodegeneration has tremendous value and point towards novel diagnostic and intervention opportunities. The current findings demonstrate that the underlying biological factors associated with neurodegeneration are different between Mexican Americans versus non-Hispanic whites as well as at different levels of disease progression.
Authors: Sid E O'Bryant; Fan Zhang; Leigh A Johnson; James Hall; Melissa Edwards; Paula Grammas; Esther Oh; Constantine G Lyketsos; Robert A Rissman Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Sid E O'Bryant; Guanghua Xiao; Robert Barber; Joan Reisch; James Hall; C Munro Cullum; Rachelle Doody; Thomas Fairchild; Perrie Adams; Kirk Wilhelmsen; Ramon Diaz-Arrastia Journal: Dement Geriatr Cogn Disord Date: 2011-08-24 Impact factor: 2.959
Authors: Clifford R Jack; Heather J Wiste; Terry M Therneau; Stephen D Weigand; David S Knopman; Michelle M Mielke; Val J Lowe; Prashanthi Vemuri; Mary M Machulda; Christopher G Schwarz; Jeffrey L Gunter; Matthew L Senjem; Jonathan Graff-Radford; David T Jones; Rosebud O Roberts; Walter A Rocca; Ronald C Petersen Journal: JAMA Date: 2019-06-18 Impact factor: 56.272
Authors: Kevin A Matthews; Wei Xu; Anne H Gaglioti; James B Holt; Janet B Croft; Dominic Mack; Lisa C McGuire Journal: Alzheimers Dement Date: 2018-09-19 Impact factor: 21.566
Authors: Melissa E Petersen; Michael S Rafii; Fan Zhang; James Hall; David Julovich; Beau M Ances; Nicole Schupf; Sharon J Krinsky-McHale; Mark Mapstone; Wayne Silverman; Ira Lott; William Klunk; Elizabeth Head; Brad Christian; Tatiana Foroud; Florence Lai; H Diana Rosas; Shahid Zaman; Mei-Cheng Wang; Benjamin Tycko; Joseph H Lee; Benjamin Handen; Sigan Hartley; Juan Fortea; Sid O'Bryant Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Sid E O'Bryant; Melissa Edwards; Leigh Johnson; James Hall; Alcibiades E Villarreal; Gabrielle B Britton; Mary Quiceno; C Munro Cullum; Neill R Graff-Radford Journal: Alzheimers Dement (Amst) Date: 2016-06-25